Jun 6 |
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
|
May 13 |
Barinthus Biotherapeutics GAAP EPS of -$0.40
|
May 13 |
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
|
May 4 |
Increases to CEO Compensation Might Be Put On Hold For Now at Barinthus Biotherapeutics plc (NASDAQ:BRNS)
|
May 1 |
Barinthus Biotherapeutics names Hooftman as chief medical officer
|
May 1 |
Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer
|
Apr 18 |
Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections
|
Mar 21 |
Barinthus Biotherapeutics GAAP EPS of -$1.91 beats by $0.05, revenue of $0.8M misses by $0.27M
|
Mar 20 |
Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments
|
Jan 5 |
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
|